Role of Suppression of Endometriosis With Progestins Before IVF-ET

National Research Centre, Egypt

Status: Completed

Conditions: Progestins; Pregnancy Rate; IVF; GnRH-analogue; Endometriosis

Treatments: Drug: leuprorelin acetate; Drug: Dienogest

Study type: Interventional

Funder types: Other

Identifiers

NCT04500743

Dienogest before IVF

Details and patient eligibility

About

This study aimed to assess the role of Dienogest pretreatment for endometriosis suppression as compared to Gonadotropin-releasing hormone agonist (GnRHa) in patients with endometriosis pursuing IVF treatment.

Enrollment: 134 patients

Sex: Female

Ages: 30 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• confirmed diagnosis of endometriosis
• body mass index < 35 Kg/m2

Exclusion criteria

• if they have been already on long-term down-regulation of the pituitary gland with GnRHa for control of endometriosis
• liver or kidney disease
• evidence of diminished ovarian reserve (e.g. high FSH level >12 IU/L or low AMH level <1 ng/ml).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

134 participants in 2 patient groups

Dienogest

Active Comparator group

Treatment:

Drug: Dienogest

GnRH analogue

Active Comparator group

Treatment:

Drug: leuprorelin acetate